• Mutation; HGNC; 427; ALK; Simple; p.Arg1275Gln (c.3824G>A); ClinVar=VCV000018083; Zygosity=Unspecified (PubMed=18724359; PubMed=28350380; DepMap).
  
• Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=9802058).
  

PubMed=9815701
Thompson J., Zamboni W.C., Cheshire P.J., Lutz L., Luo X.-L., Li Y.-L., Houghton J.A., Stewart C.F., Houghton P.J.
Efficacy of systemic administration of irinotecan against neuroblastoma xenografts.
Clin. Cancer Res. 3:423-431(1997)

PubMed=9802058
McPake C.R., Tillman D.M., Poquette C.A., George E.O., Houghton J.A., Harris L.C.
Bax is an important determinant of chemosensitivity in pediatric tumor cell lines independent of Bcl-2 expression and p53 status.
Oncol. Res. 10:235-244(1998)

PubMed=18724359; DOI=10.1038/nature07261
Mosse Y.P., Laudenslager M., Longo L., Cole K.A., Wood A., Attiyeh E.F., Laquaglia M.J., Sennett R., Lynch J.E., Perri P., Laureys G., Speleman F., Kim C., Hou C.-P., Hakonarson H., Torkamani A., Schork N.J., Brodeur G.M., Tonini G.P., Rappaport E., Devoto M., Maris J.M.
Identification of ALK as a major familial neuroblastoma predisposition gene.
Nature 455:930-935(2008)

PubMed=20922763; DOI=10.1002/pbc.22801
Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J., Reynolds C.P.
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.
Pediatr. Blood Cancer 56:239-249(2011)

PubMed=23202128; DOI=10.1038/ng.2493
Sausen M., Leary R.J., Jones S., Wu J., Reynolds C.P., Liu X.-Y., Blackford A.L., Parmigiani G., Diaz L.A. Jr., Papadopoulos N., Vogelstein B., Kinzler K.W., Velculescu V.E., Hogarty M.D.
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma.
Nat. Genet. 45:12-17(2013)

PubMed=28350380; DOI=10.1038/sdata.2017.33
Harenza J.L., Diamond M.A., Adams R.N., Song M.M., Davidson H.L., Hart L.S., Dent M.H., Fortina P., Reynolds C.P., Maris J.M.
Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines.
Sci. Data 4:170033-170033(2017)